Janux Therapeutics - JANX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $61.33
  • Forecasted Upside: 23.21%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$49.78
▲ +0.9 (1.84%)

This chart shows the closing price for JANX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Janux Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JANX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JANX

Analyst Price Target is $61.33
▲ +23.21% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Janux Therapeutics in the last 3 months. The average price target is $61.33, with a high forecast of $100.00 and a low forecast of $35.00. The average price target represents a 23.21% upside from the last price of $49.78.

This chart shows the closing price for JANX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Janux Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2024JonestradingInitiated CoverageBuy$70.00Low
3/21/2024BTIG ResearchInitiated CoverageBuy$62.00Low
3/20/2024Cantor FitzgeraldInitiated CoverageOverweight$100.00Low
3/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$24.00 ➝ $48.00Low
3/11/2024WedbushReiterated RatingOutperform$53.00Low
2/27/2024William BlairReiterated RatingOutperformLow
2/27/2024WedbushBoost TargetOutperform ➝ Outperform$24.00 ➝ $53.00Low
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00Low
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00Low
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00Low
7/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00Low
7/18/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00Low
4/5/2023WedbushInitiated CoverageOutperform$24.00Low
3/17/2023Bank of AmericaLower Target$29.00 ➝ $26.00Low
3/13/2023HC WainwrightReiterated RatingBuy$35.00Low
11/14/2022William BlairInitiated CoverageOutperformLow
7/6/2021Bank of AmericaInitiated CoverageBuy$35.00Low
7/6/2021CowenInitiated CoverageOutperformHigh
7/6/2021Evercore ISIInitiated CoverageOutperform$35.00High
7/6/2021HC WainwrightInitiated CoverageBuy$35.00High
(Data available from 4/24/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/26/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/26/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/25/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/25/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/24/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/23/2024
  • 20 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
3/24/2024
  • 8 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/23/2024

Current Sentiment

  • 8 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Janux Therapeutics logo
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $49.78
Low: $48.28
High: $50.42

50 Day Range

MA: $36.84
Low: $9.04
High: $52.65

52 Week Range

Now: $49.78
Low: $5.65
High: $58.69

Volume

706,606 shs

Average Volume

758,334 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Janux Therapeutics?

The following equities research analysts have issued research reports on Janux Therapeutics in the last year: Bank of America Co., BTIG Research, Cantor Fitzgerald, HC Wainwright, Jonestrading, Wedbush, and William Blair.
View the latest analyst ratings for JANX.

What is the current price target for Janux Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Janux Therapeutics in the last year. Their average twelve-month price target is $61.33, suggesting a possible upside of 23.2%. Cantor Fitzgerald has the highest price target set, predicting JANX will reach $100.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $35.00 for Janux Therapeutics in the next year.
View the latest price targets for JANX.

What is the current consensus analyst rating for Janux Therapeutics?

Janux Therapeutics currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe JANX will outperform the market and that investors should add to their positions of Janux Therapeutics.
View the latest ratings for JANX.

What other companies compete with Janux Therapeutics?

How do I contact Janux Therapeutics' investor relations team?

The company's listed phone number is 858-751-4493 and its investor relations email address is [email protected]. The official website for Janux Therapeutics is www.januxrx.com. Learn More about contacing Janux Therapeutics investor relations.